Cargando…
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
FB2001 is a drug candidate that targets the main protease of SARS-CoV-2 via covalently binding to cysteine 145. In this study, we evaluated the inhibitory activities of FB2001 against several SARS-CoV-2 variants in vitro and in vivo (in mice), and we also evaluated the histopathological analysis and...
Autores principales: | Shang, Weijuan, Dai, Wenhao, Yao, Cheng, Xu, Ling, Tao, Xiangming, Su, Haixia, Li, Jian, Xie, Xiong, Xu, Yechun, Hu, Min, Xie, Dong, Jiang, Hualiang, Zhang, Leike, Liu, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617675/ https://www.ncbi.nlm.nih.gov/pubmed/36354082 http://dx.doi.org/10.1016/j.antiviral.2022.105450 |
Ejemplares similares
-
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
por: Su, Haixia, et al.
Publicado: (2021) -
Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir
por: Jiang, Xiangrui, et al.
Publicado: (2023) -
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
por: Dai, Wenhao, et al.
Publicado: (2020) -
High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022) -
Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
por: Guo, Sheng, et al.
Publicado: (2021)